Clinical Trial Update: HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This pediatric Phase 1/2 clinical trial evaluates capivasertib plus venetoclax and dexamethasone for relapsed or refractory hematologic malignancies and is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Capivasertib (capivasertib)
• DEXAMETHASONE (Dexamethasone)
• Venetoclax (venetoclax)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING